The discovery of activating mutations in the EGFR gene from fifteen years ago represented a major breakthrough in the treatment of NSCLC [22, 23], as clinical responsiveness to TKIs, promising new treatment alternatives [17], turned out to be highly dependent on the presence of so-called “sensitizing” EGFR mutations [62]. Here, EGFR is linked to non-small cell lung carcinoma.